Why the study?
Does dual antiplatelet therapy pretreatment increase the risk of symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with IV thrombolysis?
Does dual antiplatelet therapy pretreatment increase the risk of symptomatic intracranial hemorrhage in patients with acute ischemic stroke treated with IV thrombolysis?
Dual antiplatelet therapy pretreatment prior to IV thrombolysis for acute ischemic stroke does not significantly increase the risk of symptomatic intracranial hemorrhage, though precision was limited.
DAPP pretreatment before IVT warrants no immediate practice change; leaves open precise bleeding risk assessment in larger studies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tsivgoulis et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: